课题基金 / 基金详情

Preclinical Vector Core

Preclinical Vector Core
临床前载体核心
批准号:
7144460
负责人:
ANDREA GAMBOTTO
金额:
$71.21万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-09-29 至 2006-08-31

项目摘要

项目成果

ANDREA GAMBOTTO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Vector Core has been and will function within the framework of the National Heart, Lung, and Blood Institute as a dynamic resource that can provide state-of-the-art viral vector technology as well as develop novel vectors. The Vector Core is able to generate retroviral, adenoviral, adeno-associated virus and herpesvirus vectors for gene delivery. The Vector Core will continue to develop and provide stocks of retroviral, adenoviral, adeno-associated and herpesviral vectors for gene delivery. The role of the Vector Core will remain to be to construct and provide vectors expressing the appropriate genes for investigators within the National Heart, Lung, and Blood Institute. In addition, the core will provide cell lines, viruses, packaging lines, plasmids, and protocols as needed to NHLBI funded investigators. The Core also will maintain to work with the NHLBI investigators to optimize viral and non-viral gene delivery and gene expression and provide technical assistance and training in the use of viral and non-viral vectors for gene transfer as needed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
U01 Proposal Transfer - 2021
  • 批准号:
    10406767
  • 项目类别:
  • 资助金额:
    $325.08万
  • 财政年份:
    2019
  • 负责人:
    ANDREA GAMBOTTO
  • 依托单位:
Pre-clinical evaluation of a Zika virus vaccine
Pre-clinical evaluation of an adenoviral-based MERS-CoV vaccine
Pre-clinical evaluation of an adenoviral-based MERS-CoV vaccine
海外基金